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An unexpected outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) 
infection occurred between May and July 2015 in South Korea [1]. 
 Although a role for antivirals in the treatment of MERS has not been definitively prov-
en, antiviral treatment may be considered in addition to appropriate supportive care 
for MERS [2]. A combination regimen of type 1 interferon, ribavirin, and lopinavir/rito-
navir is recommended for antiviral treatment of MERS. It is yet unknown whether an-
tiviral treatment for MERS could affect the production and persistence of neutralizing 
antibodies over time. 
 We evaluated the neutralizing activity in serum from three patients >1 year after re-
covery from MERS-CoV infection associated with mild pneumonia treated with anti-
virals during the MERS outbreak in South Korea. 
 Three individuals <50 years, who successfully recovered from MERS-CoV infection 
without any complications, were enrolled in this study. A total of 10 mL blood was col-
lected in acid citrate dextrose tubes from each patient. This study was approved by the 
Institutional Review Board (IRB) of Severance Hospital (4-2015-1066). The study was 
conducted in compliance with local IRB guidelines and with the participants’ written 
informed consent. 
 MERS-CoV pseudovirus was generated and Western blots were performed to detect 
MERS-CoV S protein in the pseudovirus generated, as previously described with some 
modifications [3,4]. Briefly, 293T cells (ATCC, Manassas, VA, USA) were co-transfected 
with 20 μg of recombinant MERS-CoV plasmid, containing the full-length S proteins 
(Sino Biological Inc., Wayne, PA, USA), and 20 μg of plasmid encoding Env-defective, 
luciferase expressing HIV-1 (pNL4-3.luc.RE from AIDS Reagent Program of National 
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We evaluated the neutralizing activity in serum from three patients >1 year after recovery from 
Middle East respiratory syndrome (MERS) associated with mild pneumonia treated with anti-
virals during the MERS outbreak in South Korea at 2015. The neutralizing activity in serum was 
measured by pseudovirus inhibition assays. Three-fold diluted serum of subjects showed only 
9.7%, 10.3%, and 2.2% reductions in relative light units. So, significant neutralizing activity was 
not demonstrated in any sera of three patients with mild pneumonia >1 year after being suc-
cessfully treated with antiviral agents and recovering from MERS coronavirus infection.
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Institutes of Health) in a T175 tissue culture flask, using the 
calcium phosphate method. The cells were changed into fresh 
Dulbecco’s modified Eagle’s medium 8 hours later. Superna-
tants were harvested 72-hour post-transfection and used as a 
source of pseudoviruses for single-cycle infection. 
 A pseudovirus inhibition assay was established to detect 
neutralizing activity in patient sera [4,5]. Pseudovirus-con-
taining supernatants were incubated with serially diluted pa-
tient serum at 37°C for 1 hour before addition to target cells 
(Vero cells) pre-plated in 96-well culture plates (104 cells/well). 
The media was replaced after 24 hours, followed by lysis of 
the cells 72 hours later using cell lysis buffer (Perkin-Elmer, 
Waltham, MA, USA), with the lysates transferred into 96-well 
luminometer plates. Luciferase substrate (Perkin-Elmer) was 
added to the plates, and the relative luciferase activity was 
determined. The inhibition of MERS-CoV pseudovirus was 
presented as percentage inhibition of relative light units (RLU). 
Control serum was collected from a healthy volunteer.
 Subject 1 was a 38-year-old man diagnosed with MERS-
CoV infection by real time polymerase chain reaction (PCR) 
of nasopharyngeal aspirate on 13 June 2015. He was an am-
bulance driver exposed to a MERS-CoV infected patient dur-
ing patient transfer on 5-6 June 2015. Symptoms including fe-
ver, myalgia, and headache appeared after 10 June 2015. He 
did not have a cough, sputum production, dyspnea, or other 
respiratory symptoms, but chest radiography performed on 
13 June 2015 showed pneumonic consolidation on the right 
lower lung field. He was treated with combination of interferon-
α2a (180 µg/wk), ribavirin (2,000 mg loading followed by 1,200 
mg every 8 hours for 4 days and 600 mg every 8 hours), and 
lopinavir/ritonavir (400 mg/100 mg orally every 12 hours) from 
15-24 June 2015. Repeated MERS-CoV PCR tests showed neg-
ative results on 23 and 24 June 2015. Full recovery was achieved 
without any complications, and a blood sample was collected 
on 1 July 2016. 
 Subject 2 was a 33-year-old woman diagnosed with MERS-
CoV infection on 9 June 2015. She was indirectly exposed to 
MERS-CoV between 25 and 29 May 2015 at another hospital, 
where MERS-CoV infections were diagnosed in a multi-bed 
room. Diarrhea commenced 5 days prior to diagnosis, with 
fever, myalgia, sore throat, cough, sputum production, and 
mild dyspnea commencing 4 days before diagnosis. Chest 
radiography showed peribronchial pneumonic consolidation 
in the right middle lung field. Between 9 and 12 June 2015, 
the patient was treated with a combination of interferon-α2a, 
ribavirin, and lopinavir/ritonavir. From 13 June 2015, lopina-
vir/ritonavir was discontinued and the ribavirin dose was re-
duced to 10 mg/kg every 8 hours due to jaundice. Two con-
secutive negative results of MERS-CoV PCR were confirmed 
on 23 and 24 June 2015. Full recovery was achieved without 
any complications, and a blood sample was collected on 1 
July 2016. 
 Subject 3 was a 45-year-old man diagnosed with MERS-
CoV infection on 14 June 2015. He was exposed to a MERS-
CoV infected patient on 6 June 2015 and high fever, myalgia, 
and coughing commenced on 13 June 2015. Chest radiogra-
phy showed pneumonic consolidation on the left middle and 
right lower lung fields. He was treated with a combination of 
interferon-α2a, ribavirin, and lopinavir/ritonavir from 16-28 
June 2015. Two consecutive negative results of MERS-CoV 
PCR were confirmed on 27 and 28 June 2015. The fever sub-
sided 3 days after initiation of treatment associated with im-
provement on chest radiography. Full recovery was achieved 
without any complications, and a blood sample was collected 
on 29 September 2016. 
 All subjects had no underlying comorbidities. 
 A Western blot to identify the incorporation of MERS-CoV 
S protein in the packaged MERS-CoV pseudovirus showed a 
clear band corresponding to the MERS-CoV S protein. 
 As shown in Fig. 1, three-fold diluted serum of subjects 1 
and 2 showed only 9.7% and 10.3% reductions in RLU, respec-
tively, while that of subject 3 showed only a 2.2% reduction. 
Fig. 1. Inhibitory activity of patients’ sera against Middle East respira-
tory syndrome coronavirus pseudovirus infection. Three-fold diluted 
serum of subjects 1 and 2 showed only 9.7% and 10.3% reductions in 
relative light unit (RLU), respectively, while that of subject 3 showed 
only a 2.2% reduction. Control serum was collected from a healthy 
volunteer. 
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 The findings of this study are inconsistent with previous 
observations. A previous study on severe acute respiratory 
syndrome coronavirus (SARS-CoV) infection found that 93.88% 
and 89.58% of patients were IgG positive at 1- and 2-year post-
symptom onset, respectively [6]. However, 3 years later, only 
53.57% of the population had SARS-CoV specific IgG. A study 
on antibodies against MERS-CoV, including neutralizing an-
tibodies, showed antibody persistence in six of seven individ-
uals (86%), 34 months after the 2012 MERS-CoV outbreak in 
Jordan [7]. All seven subjects had respiratory symptoms and 
few underlying diseases, and five had substantial pneumo-
nia. Mild or asymptomatic MERS-CoV infections could po-
tentially be associated with development of lower levels of 
MERS-CoV neutralizing antibodies over time [8]. Patients from 
the above study might not have been treated with antivirals. 
Subjects in our study were also young and healthy, with mild 
pneumonic consolidations at admission. Moreover, all pa-
tients in our study were treated with interferon-α, ribavirin, 
and lopinavir/ritonavir. Antiviral treatment for MERS associ-
ated with mild pneumonia might decrease viral replication 
and reduce antibody responses in the early stages of the dis-
eases, resulting in the identified low-level neutralizing activity 
within convalescent serum. 
 The small number of subjects is an important limitation of 
this study. Furthermore, we could not evaluate paired sera 
comparing the early stage of illness and 1-year post-recovery. 
The viral load at early infection time may be associated with 
the neutralizing antibody and the disease outcome, but we 
could not collect data on the viral load of subjects. In addi-
tion, we could not validate the pseudovirus inhibition assay 
with positive control, and subjects without treatment could 
not be enrolled for comparisons. 
 In conclusion, neutralizing activity was not demonstrated 
in any sera of three patients with mild pneumonia >1 year af-
ter being successfully treated with antiviral agents and recov-
ering from MERS-CoV infection. 
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